Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 47,918 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 47,918 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total value of $2,132,351.00. Following the completion of the transaction, the executive vice president owned 616,106 shares in the company, valued at $27,416,717. The trade was a 7.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Dana Aftab also recently made the following trade(s):

• On Thursday, February 19th, Dana Aftab sold 29,873 shares of Exelixis stock. The stock was sold at an average price of $44.35, for a total transaction of $1,324,867.55.

Exelixis Trading Down 1.1%

Exelixis stock traded down $0.47 during trading hours on Thursday, reaching $44.28. 2,713,840 shares of the stock were exchanged, compared to its average volume of 2,634,991. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62. The company has a market cap of $11.50 billion, a P/E ratio of 15.99, a price-to-earnings-growth ratio of 1.02 and a beta of 0.42. The stock has a 50 day moving average of $44.06 and a two-hundred day moving average of $41.37.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The company had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.55 EPS. On average, analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on EXEL. Morgan Stanley raised their price target on shares of Exelixis from $48.00 to $49.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Citigroup lowered Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Bank of America downgraded Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price for the company. in a research report on Monday, January 5th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Finally, Wolfe Research started coverage on shares of Exelixis in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $47.11.

Institutional Investors Weigh In On Exelixis

Hedge funds have recently added to or reduced their stakes in the business. Richardson Financial Services Inc. raised its holdings in Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after buying an additional 292 shares during the last quarter. Anchor Investment Management LLC lifted its holdings in shares of Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. Motiv8 Investments LLC purchased a new position in shares of Exelixis during the fourth quarter valued at approximately $26,000. Root Financial Partners LLC bought a new stake in Exelixis during the third quarter worth $28,000. Finally, Acumen Wealth Advisors LLC purchased a new stake in Exelixis in the 4th quarter valued at $29,000. 85.27% of the stock is currently owned by institutional investors.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.